Phase 3 Prostate Cancer Trial, Recruiting NCT03258320 Sponsor: Shanghai Jiao Tong University School of Medicine Condition: Prostate Cancer
Back to Prostate Cancer

Phase 3 Prostate Cancer Trial, Recruiting

NCT03258320
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged between 40 and 75 years old who have been diagnosed with prostate cancer confirmed by a tissue biopsy.
  • People whose major organs (such as the heart, liver, and kidneys) are functioning without severe problems.
  • People who are generally able to carry out daily activities with no or only minor limitations, as measured by a standard health scale used by doctors (WHO performance status of 0 or 1).
  • People who have not previously had chemotherapy for any cancer.
  • People whose prostate cancer has been assessed as being at a certain stage of local spread (Clinical Stage T2c or higher, meaning the cancer has grown to affect both sides of the prostate), but ideally has not spread to distant parts of the body, as determined by a CT scan before any surgery.

Who may not be able to join:

  • People aged 76 or older.
  • People with severe problems affecting a major organ.
  • People whose general health or ability to carry out daily activities is significantly limited (WHO performance status greater than 1).
  • People who have previously received chemotherapy for cancer.
  • People whose prostate cancer has been classified as Stage IV, meaning it has spread significantly beyond the prostate.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Yu Sun, Ph.D, Shanghai Jiao Tong University School of Medicine

Phone: 86-21-54923302

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Shanghai Jiao Tong University School of Medicine
Registry
ClinicalTrials.gov
Start date
1 January 2015
Est. completion
1 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

5 years disease-free survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov